健保藥品的HTA評估報告
- 161 Ninlaro Capsules 4mg、3mg、2.3mg
- 162 Kyprolis for Injection
- 163 Fluzole powder for oral suspension 40mg/mL
- 164 Curosurf® Endotracheobronchial Suspension
- 165 血甯博皮下注射劑 30 毫克/毫升、150 毫克/毫升(Hemlibra SC injection 30mg/mL、150mg/mL)
- 166 吉他韋膜衣錠 (Biktarvy Tablets)
- 167 滋若愷膜衣錠 (Juluca film coated tablets)
- 168 杜避炎注射劑 300 毫克(DUPIXENT solution for injection 300mg)
- 169 癌必定膜衣錠 20 毫克、40 毫克及60 毫克 (Cabometyx film-coated tablet 20 mg、40 mg、60 mg)
- 170 沛斯博凍晶注射劑 1 毫克 (BESPONSA 1 mg Powder for Concentrate for Solution for Infusion)
- 171 Kisqali 200mg Film-Coated Tablets
- 172 瑪威克錠 10 毫克(MAVENCLAD Tablets 10mg)
- 173 Venclexta Film-Coated Tablets
- 174 Imbruvica Capsules
- 175 可帝敏持續性釋放錠 9 毫克(Cortiment MMX 9 mg prolonged release tablets)
- 176 Soliqua solution for injection
- 177 Tresiba FlexTouch (Insulin Degludc Injection)
- 178 控糖穩膜衣錠 5 毫克/10 毫克(Qtern 5mg/10mg Film-Coated Tablets)
- 179 佳腎康錠Jinarc(15mg、30mg、45mg、60mg、90mg)
- 180 穩適妥 5 毫克膜衣錠(steglatro 5mg film-coated tablets)